|
| |
$9.8 Billion
World Implantable/Injectable Drug Delivery Market Set for Healthy Growth
New York, February 26, 2007 — Led by the strong growth of
biotechnology drugs requiring novel delivery technologies, the injectable/implantable
drug delivery market reached revenues of $9.8 billion in 2006, according to
Drug Delivery Markets, Second Edition, Vol.2: Implantable/Injectable Delivery
Systems, a new market research study from Kalorama
Information.
The market is dominated by implantable, sustained-release, and
targeted-injection drug delivery systems with manufacturer revenues of
approximately $7.3 billion in 2006, an increase of 6.3% over 2002 sales. Growth
continues to be fueled by the introduction of biological therapies, including
blood modifiers and insulin products, with the sector projected to reach $9
billion by 2010.
Implantable technologies have been successfully utilized in administering
anti-cancer therapeutics as well as the administration of high drug doses in
traditionally inaccessible areas, such as the central nervous system, bone
tissue, and beyond the blood–retinal barrier.
Also fueling growth is the needle-free sector with revenues expected to reach $3
billion by 2010. An expanding drug delivery marketplace, increasing consumer
awareness, and growing focus on healthcare worker safety could help drive demand
for needle-free systems.
The report accurately assesses the two-fold nature of the market, which
encompasses drug delivery technology and the revenues earned from licensing that
technology as well as the pharmaceutical products that utilize the drug delivery
technology. Revenues reported include pharmaceutical sales for products
utilizing implant and injection technologies making Kalorama’s market assessment
the most well-rounded analysis of the entire market for injectable/implantable
drug delivery.
“The development of better delivery systems in conjunction with the discovery of
novel pharmacological compounds will lead to significant improvements in drug
delivery,” notes Mary Anne Crandall, the report’s author. “This is a dynamic
market expected to increase at break-neck speed during the forecast period.
Significant revenue increases are anticipated particularly in the needle-free
delivery of injectable medications, especially in the vaccine arena.”
Drug Delivery Markets, Second Edition, Vol.2: Implantable/Injectable Delivery
Systems also includes extensive discussions of key
trends and developments, in-depth company profiles of market leaders and niche
players.
About Kalorama Information
Kalorama Information, a division of MarketResearch, supplies the latest
in independent market research for the life sciences. To view their catalogue go
to:
http://www.bioportfolio.com/cgi-bin/acatalog/Kalorama.html
| |
|
